Growth Metrics

Oncology Institute (TOI) Amortization of Deferred Charges (2021 - 2025)

Oncology Institute's Amortization of Deferred Charges history spans 5 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges fell 24.4% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $8.4 million, up 32.89%, while the annual FY2025 figure was $8.4 million, 32.91% up from the prior year.
  • Amortization of Deferred Charges reached $1.2 million in Q4 2025 per TOI's latest filing, up from $1.2 million in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $4.9 million in Q1 2025 to a low of $17000.0 in Q2 2021.
  • Average Amortization of Deferred Charges over 5 years is $1.4 million, with a median of $1.5 million recorded in 2023.
  • Peak YoY movement for Amortization of Deferred Charges: surged 4855.56% in 2022, then dropped 27.86% in 2025.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $18000.0 in 2021, then surged by 8522.22% to $1.6 million in 2022, then rose by 1.29% to $1.6 million in 2023, then increased by 1.4% to $1.6 million in 2024, then decreased by 24.4% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Amortization of Deferred Charges are $1.2 million (Q4 2025), $1.2 million (Q3 2025), and $1.1 million (Q2 2025).